Case Reports in Oncology
Scope & Guideline
Transforming Case Studies into Global Knowledge
Introduction
Aims and Scopes
- Case Reports of Rare Cancers:
The journal emphasizes the importance of documenting unusual cancer presentations and rare malignancies, providing valuable insights into their clinical management and treatment. - Innovative Treatment Approaches:
It highlights case reports that explore new treatment modalities, including targeted therapies, immunotherapies, and combination regimens, showcasing their efficacy and safety in various cancer types. - Multidisciplinary Perspectives:
The journal encourages submissions that reflect a multidisciplinary approach to cancer care, integrating input from medical oncologists, surgeons, radiologists, and pathologists. - Patient Outcomes and Follow-ups:
The focus is on detailed follow-up of patients post-treatment, providing data on long-term outcomes, recurrence rates, and survival, which are crucial for improving clinical practices. - Emerging Genetic and Molecular Insights:
The journal includes case reports that delve into the genetic and molecular underpinnings of cancers, enhancing the understanding of tumor biology and potential targeted therapies.
Trending and Emerging
- Immunotherapy and Targeted Therapies:
There is a significant rise in case reports documenting the use of immunotherapy and targeted therapies, showcasing their effectiveness and expanding the therapeutic options available to patients. - Personalized Medicine:
Emerging themes include case reports that focus on personalized treatment approaches based on genetic testing and molecular profiling, highlighting the shift towards tailored cancer therapy. - Combination Therapies:
The journal increasingly features reports on novel combination therapies, illustrating the trend towards integrating various treatment modalities for enhanced efficacy. - Long-Term Follow-Up Studies:
A growing number of submissions emphasize long-term follow-up and outcomes, reflecting the importance of understanding the durability of treatment responses and late effects. - Real-World Evidence and Patient Experiences:
There is a trend towards incorporating real-world evidence and patient-reported outcomes in case reports, providing insights into the practical implications of treatments in everyday clinical settings.
Declining or Waning
- Traditional Chemotherapy Case Reports:
There has been a noticeable decrease in case reports focusing solely on traditional chemotherapy treatments, as the oncology field increasingly emphasizes targeted therapies and immunotherapy. - Standard Surgical Techniques:
Case reports detailing standard surgical approaches without new insights or innovations are becoming less common, as the focus shifts towards minimally invasive procedures and novel surgical techniques. - Palliative Care Cases:
The frequency of case reports centered on palliative care alone has diminished, possibly due to a growing emphasis on curative and transformative therapies in oncology. - Common Cancer Types:
Reports on well-known malignancies, such as breast and lung cancer, without unique angles or significant clinical insights are less frequently submitted, indicating a preference for more complex or rare cases. - Historical Treatment Comparisons:
There is a decline in the publication of case reports comparing historical treatment regimens, as the field rapidly evolves and focuses on contemporary practices.
Similar Journals
BMJ Case Reports
Uncovering Rare Medical Narratives for Enhanced CareBMJ Case Reports is a vital resource within the field of medicine, published by the esteemed BMJ PUBLISHING GROUP. With an E-ISSN of 1757-790X and a focus on disseminating high-quality case reports, this journal serves as a platform for healthcare professionals, researchers, and students to share unique clinical experiences and uncommon presentations of medical conditions. Since its inception in 2008 and continuing through 2024, it has gained recognition for contributing to the advancement of medical knowledge, currently ranking at Q4 in the Medicine (miscellaneous) category and positioned in the 54th percentile in General Medicine according to Scopus rankings. Although it is a subscription-based journal, its impact on clinical practice and education is significant, enabling practitioners to learn from diverse case studies and improving patient care outcomes. As it aims to enhance the understanding of rare and significant medical cases, BMJ Case Reports remains an essential publication for those at the forefront of medical innovation.
Thoracic and Cardiovascular Surgeon Reports
Elevating standards in thoracic and cardiovascular surgical reporting.Thoracic and Cardiovascular Surgeon Reports is a pivotal academic journal dedicated to the dissemination of innovative research and clinical practices in the fields of thoracic and cardiovascular surgery. Published by GEORG THIEME VERLAG KG, this journal has been an open-access publication since 2013, fostering a broader reach and enhancing visibility for authors and researchers globally. With its commitment to high-quality peer-reviewed articles, Thoracic and Cardiovascular Surgeon Reports serves as an essential platform for surgeons, clinicians, and scholars to share findings that advance medical knowledge, improve patient outcomes, and refine surgical techniques. The journal aims to bridge the gap between research and practical application, catering to an audience keen on staying updated with the latest in thoracic and cardiovascular interventions, making it a valuable resource in an ever-evolving medical landscape.
ACG Case Reports Journal
Elevating Medical Practice Through Shared ExperiencesACG Case Reports Journal, published by Lippincott Williams & Wilkins, is a pivotal resource in the realm of gastrointestinal medicine and clinical practice. Since its inception in 2014, this open-access journal has dedicated itself to disseminating high-quality case reports that contribute to the evolving understanding of gastrointestinal diseases and their management. With an impressive ranking of #203 out of 529 in the General Medicine category according to Scopus, placing it in the 61st percentile, the journal underscores its significant role in advancing medical knowledge. This accessibility allows researchers, healthcare professionals, and students to engage with groundbreaking case studies, enriching their expertise and promoting informed clinical decision-making. ACG Case Reports Journal aims to foster a collaborative environment where innovative ideas and clinical experiences converge, ultimately enhancing patient care and outcomes in the field of gastroenterology.
Indian Journal of Medical and Paediatric Oncology
Advancing pediatric oncology through innovative research.Indian Journal of Medical and Paediatric Oncology, published by THIEME MEDICAL PUBL INC, serves as a crucial platform for disseminating research and clinical studies in the realms of oncology and paediatrics. With an ISSN of 0971-5851 and an E-ISSN of 0975-2129, this journal plays a pivotal role in addressing the challenges and advancements in important areas of child health and cancer treatment. Although the journal is currently ranked in the Q4 category for both Oncology and Pediatrics, Perinatology and Child Health, its ongoing commitment to publishing quality research from 2009 to 2024 signifies its relevance in the academic community. Positioned in India and accessible to a global audience, this journal aims to foster a comprehensive understanding of medical and paediatric oncology, thereby influencing clinical practices and enhancing patient care. Researchers, practitioners, and students alike can benefit from its diverse range of articles, offering insights into the latest scientific discoveries and therapeutic approaches in these critical fields.
Nature Reviews Clinical Oncology
Pioneering Insights for Tomorrow's TreatmentsNature Reviews Clinical Oncology is a premier journal dedicated to the comprehensive exploration and critical evaluation of current advancements in the field of clinical oncology. Published by the esteemed NATURE PORTFOLIO in the United Kingdom, this influential journal boasts an impressive impact factor that reflects its significant role in shaping oncology research. As a Q1 ranked journal in Scopus, it occupies a notable position within the top tier of oncology publications, placing it in the 99th percentile among its peers. With a history of convergence from 2009 to 2024, it presents high-quality content through an open-access model, ensuring accessibility to vital research findings. Researchers, professionals, and students alike will find Nature Reviews Clinical Oncology an invaluable resource for staying abreast of the latest trends, biologic insights, and therapeutic innovations that drive the future of cancer treatment.
Blood and Lymphatic Cancer-Targets and Therapy
Transforming Cancer Treatment Through Open AccessBlood and Lymphatic Cancer-Targets and Therapy, published by DOVE MEDICAL PRESS LTD, is a vital open-access journal that has been disseminating crucial research and findings in the field of hematology and oncology since 2011. With its ISSN 1179-9889, this journal focuses on the latest therapeutic targets and innovative treatment strategies for blood and lymphatic cancers, contributing significantly to the advancement of knowledge and practice in this specialized area. Designed for researchers, healthcare professionals, and students alike, Blood and Lymphatic Cancer-Targets and Therapy aims to foster a deeper understanding of cancer biology and promote collaborative efforts leading to novel therapeutic interventions. The open-access model ensures that research findings are readily accessible to a global audience, underscoring the journal's commitment to enhancing patient care and fostering educational growth in the cancer domain.
Chinese Clinical Oncology
Transforming the landscape of cancer treatment and research.Chinese Clinical Oncology is a distinguished journal dedicated to advancing the field of oncology and clinical research, published by AME Publishing Company. Since its inception in 2012, this journal has established its significance within the academic community, boasting an impactful presence as evidenced by its 2023 Scopus rankings, where it is positioned in the 47th percentile in the field of oncology. This open access journal features a diverse range of research, reviews, and clinical studies that aim to bridge the gap between experimental and clinical oncology, making it an invaluable resource for researchers, medical professionals, and students alike. The journal is based in Hong Kong and is committed to publishing studies that contribute to the understanding and treatment of cancer, with a strong focus on innovative methodologies and emerging therapies. With a current categorization of Q2 in Medicine and Q3 in Oncology, Chinese Clinical Oncology offers a robust platform for scholarly communication and is pivotal for those involved in cancer research and treatment.
LEUKEMIA RESEARCH
Elevating the standards of leukemia research and care.Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.
Cancer Radiotherapie
Advancing cancer care through innovative radiotherapy research.Cancer Radiotherapie, published by Elsevier, is a respected academic journal dedicated to advancing the field of oncology and radiology through original research and comprehensive reviews. With an ISSN of 1278-3218 and an E-ISSN of 1769-6658, the journal serves as a vital platform for disseminating knowledge and innovation in cancer treatment methodologies, specifically focusing on radiotherapy. As of 2023, it holds a Category Quartile of Q3 in both Oncology and Radiology, Nuclear Medicine and Imaging, reflecting its significance within these domains amidst a competitive landscape. Despite its current rankings—205th out of 333 in Radiology and 269th out of 404 in Oncology—it continuously strives to build a reputable presence with contributions that push the boundaries of cancer therapy. Although open access options are not available, the journal is committed to ensuring that valuable insights reach healthcare professionals and researchers worldwide, contributing to improved patient outcomes and advancements in treatment efficacy.
Molecular and Clinical Oncology
Connecting researchers to revolutionize cancer treatment.Molecular and Clinical Oncology is a dynamic journal published by SPANDIDOS PUBL LTD, aimed at advancing the understanding of cancer biology and treatment modalities. With an ISSN of 2049-9450 and an E-ISSN of 2049-9469, the journal serves as a critical platform for researchers and clinicians dedicated to uncovering novel insights in molecular oncology and enhancing clinical practices. As a testament to its growing influence, the journal has achieved a Q3 ranking in Oncology and a Q4 ranking in Cancer Research for the year 2023, reflecting its commitment to publishing high-quality research. Although currently not an Open Access publication, the journal offers crucial subscription options, ensuring comprehensive access to groundbreaking studies and innovations in the field. With converged years spanning 2018 to 2024, the journal is set to continue enriching the academic community with its valuable contributions, ultimately empowering researchers, professionals, and students engaged in the fight against cancer.